ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · Real-Time Price · USD
0.3274
-0.0266 (-7.51%)
At close: Aug 13, 2025, 4:00 PM
0.3238
-0.0036 (-1.10%)
After-hours: Aug 13, 2025, 7:01 PM EDT
ProPhase Labs Revenue
ProPhase Labs had revenue of $1.25M in the quarter ending June 30, 2025, a decrease of -49.60%. This brings the company's revenue in the last twelve months to $4.62M, down -36.69% year-over-year. In the year 2024, ProPhase Labs had annual revenue of $6.77M, down -80.65%.
Revenue (ttm)
$4.62M
Revenue Growth
-36.69%
P/S Ratio
1.50
Revenue / Employee
$48,104
Employees
96
Market Cap
13.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.77M | -28.21M | -80.65% |
Dec 31, 2023 | 34.98M | -87.66M | -71.48% |
Dec 31, 2022 | 122.65M | 43.61M | 55.17% |
Dec 31, 2021 | 79.04M | 64.53M | 444.59% |
Dec 31, 2020 | 14.51M | 4.64M | 46.96% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PRPH News
- 11 hours ago - ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 - GlobeNewsWire
- 1 day ago - ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment - GlobeNewsWire
- 2 days ago - ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025 - GlobeNewsWire
- 15 days ago - ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement - GlobeNewsWire
- 21 days ago - ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing - GlobeNewsWire
- 23 days ago - ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative - GlobeNewsWire
- 6 weeks ago - ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - GlobeNewsWire
- 2 months ago - ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer - GlobeNewsWire